Table 1.
Proliferation and migration of endothelial cells in response to CM from ovarian cancer cells modified by senescent HPMCs upon neutralization of individual angiogenesis mediators in cancer cell-derived CM
| Neutralized mediator | HUVEC proliferation | HUVEC migration | ||||
|---|---|---|---|---|---|---|
| A2780 | OVCAR-3 | SKOV-3 | A2780 | OVCAR-3 | SKOV-3 | |
| CXCL1 | 98 ± 6 | 77 ± 5* | 56 ± 1* | 100 ± 3 | 95 ± 8 | 67 ± 7* |
| CXCL8 | 104 ± 8 | 88 ± 2* | 89 ± 3* | 104 ± 4 | 44 ± 2* | 41 ± 3* |
| HGF | 55 ± 6* | 103 ± 7 | 98 ± 4 | 78 ± 3* | 102 ± 3 | 99 ± 2 |
| VEGF | 65 ± 4* | 102 ± 5 | 45 ± 2* | 66 ± 1* | 101 ± 4 | 45 ± 4* |
The values are expressed as a percentage of endothelial cell proliferation/migration upon treatment with an intact CM from cancer cells pre-incubated with CM from senescent HPMCs (considered as 100 %). The concentrations of antibodies used here are provided in the "Materials and methods" section. The results derive from experiments performed with CM generated by HPMCs from 8 different donors. Cancer cells and endothelial cells were used in hexaplicates. The asterisks indicate a significant decrease in endothelial cell proliferation/migration